Manel Esteller

Manel Esteller

Doctor Manel Esteller received his undergraduate degree in Medicine at the University of Barcelona in 1992 and went on to earn a specialized doctorate from the same university in the Molecular Genetics of Endometrial Carcinoma in 1996. He was a guest researcher at the School of Biological and Medical Sciences of the University of St. Andrews (Scotland, UK), where his research focused on the molecular genetics of hereditary breast cancer. From 1997 to 2001, Esteller was a post-doctoral research and adjunct researcher at Johns Hopkins University School of Medicine (Baltimore, MD, USA), where he studied DNA methylation and its relationship with cancer in humans. His results were decisive in establishing that the hypermethylation of tumour suppressor genes is a characteristic trait of human tumours. From October 2001 to September 2008, Dr. Esteller directed the Epigenetic Cancer Laboratory at the National Centre for Oncology Research (CNIO) in Madrid.

Since October 2008, Dr. Esteller has been the director of the Cancer Epigenetics and Biology Program of the Bellvitge Biomedical Research Institute (IDIBELL) and the leader of the Cancer Epigenetics Group, as well as a lecturer in genetics at the Department of Physiological Sciences II of the Faculty of Medicine of the University of Barcelona and research professor at the Catalan Institute for Research and Advanced Studies (ICREA). He is the author of more than three hundred original, accredited manuscripts in the sphere of biomedical sciences, is a member of numerous international societies and publishing associations and performs peer reviews for several journals and sponsored entities. His numerous achievements include the Prize for Basic Research at Johns Hopkins University and Medical Institution (1999), the Carcinogenesis Award (2005),  the Swiss Bridge Award (2006), the Innovation Award of the Commonwealth of Massachusetts (2007), the Debiopharm-EPFL Award (2008), the Josef Steiner Cancer Research Award (2009), the Lilly Foundation Award for Preclinical Biomedical Research (2009), the Carmen y Severo Ochoa Award for Molecular Research (2009) and the World Health Summit and Pfizer Award for Innovation in Biomedical Research (2010). He has recently been elected Elected Academician of the Academy of Medicine of Catalonia for his contribution to the study of epigenetics in health and disease.